Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting

Key Takeaways

• 173 patients treated; 64 NSCLC, 44 breast, 23 other tumors.
• 50% ORR in squamous NSCLC at 4.5 mg/kg; 94% disease control.
• Low‑grade TRAEs dominate; no grade 4/5 events reported.
• Responses observed in EGFR‑mutant NSCLC, HR+ and triple‑negative breast cancer.
• JK06’s biparatopic design targets 5T4 across multiple solid tumors.

Pulse Analysis

Antibody‑drug conjugates (ADCs) have reshaped oncology by delivering potent cytotoxins directly to tumor cells, and the 5T4 antigen is emerging as a compelling target due to its restricted expression on embryonic tissues and over‑representation in aggressive solid tumors. SalubrisBio’s JK06 leverages a quadrivalent, biparatopic architecture that binds 5T4 with picomolar affinity and carries a monomethyl auristatin E (MMAE) payload. This design promises enhanced internalization and uniform payload delivery, differentiating JK06 from earlier single‑epitope ADCs and aligning with industry trends toward multi‑epitope targeting for improved efficacy.

The Phase 1/2 trial’s efficacy signals are noteworthy, especially the 50% ORR observed in squamous NSCLC patients receiving 4.5 mg/kg—a cohort historically refractory to standard therapies. Across all squamous NSCLC participants, a 35% ORR coupled with a 94% disease‑control rate suggests durable tumor suppression. Equally compelling are the responses in EGFR‑mutant NSCLC (43% ORR) and breast cancer subtypes, including a 30% ORR in hormone‑receptor‑positive disease and 25% in triple‑negative cases, many of which had prior ADC exposure. These outcomes indicate JK06’s potential to overcome resistance mechanisms that limit existing ADCs.

Safety remains a pivotal factor for ADC adoption, and JK06’s profile appears favorable. Treatment‑related adverse events were predominantly low‑grade, with alopecia, asthenia, dry eye, fatigue and nausea each affecting ≤15% of patients, and no grade 4/5 events recorded. The low incidence of dose reductions and discontinuations underscores tolerability at doses ≤5.2 mg/kg. As SalubrisBio moves toward larger expansion cohorts and combination studies, JK06 could carve a niche alongside competitors such as Mirati’s sitravatinib‑ADC and AstraZeneca’s trastuzumab‑deruxtecan, particularly in 5T4‑expressing malignancies where therapeutic options are limited. The forthcoming data will be critical for investors and clinicians assessing the ADC’s commercial viability.